HE4 As a Serum Biomarker for ROMA Prediction and Prognosis of Epithelial Ovarian Cancer

Wen-Ting Chen,Xiang Gao,Xiao-Dian Han,Hui Zheng,Lin Guo,Ren-Quan Lu
DOI: https://doi.org/10.7314/apjcp.2014.15.1.101
2014-01-01
Asian Pacific Journal of Cancer Prevention
Abstract:BACKGROUND AND PURPOSE:Human epididymis protein 4 (HE4) has been suggested to be a novel biomarker of epithelial ovarian cancer (EOC). The present study aimed to evaluate and compare HE4 with the commonly used marker, carbohydrate antigen 125 (CA125), in prediction and therapy-monitoring of EOC.PATIENTS AND METHODS:Serum HE4 concentrations from 123 ovarian cancer patients and 174 controls were measured by Roche electrochemiluminescent immunoassay (ECLIA). Risk of ovarian malignancy algorithm (ROMA) values were calculated and assessed. In addition, the prospects of HE4 detection for therapy-monitoring were evaluated in EOC patients.RESULTS:The ROMA score could classify patients into high- and low-risk groups with malignancy. Indeed, lower serum HE4 was significantly associated with successful surgical therapy. Specifically, 38 patients with EOC exhibited a greater decline of HE4 compared with CA125. In contrast, elevation of HE4 better predicted recurrence (of 46, 11 patients developed recurrence, and with it increased HE4 serum concentrations) and a poor prognosis than CA125.CONCLUSIONS:This study suggests that serum HE4 levels are closely associated with outcome of surgical therapy and disease prognosis in Chinese EOC patients.
What problem does this paper attempt to address?